Adaptimmune Therapeutics plc
Balance Sheet
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $91.1M | $144.0M | $108.0M | $149.9M | $56.9M | $50.4M | $68.4M | $84.0M |
| Accounts Receivable | $1.5M | $821.0K | $7.4M | $752.0K | $139.0K | — | $192.0K | $206.0K |
| Inventory | $7.3M | — | — | — | — | — | — | — |
| Total Current Assets | $188.2M | $207.6M | $255.4M | $415.5M | $398.2M | $120.5M | $231.1M | $230.2M |
| Property, Plant & Equipment | $31.3M | $50.9M | $53.5M | $30.5M | $27.8M | $31.1M | $36.1M | $40.7M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $3.9M | $330.0K | $442.0K | $1.0M | $1.7M | $2.2M | $1.5M | $1.3M |
| Total Assets | $246.0M | $282.6M | $328.9M | $469.5M | $451.1M | $181.5M | $276.7M | $281.1M |
| Liabilities | ||||||||
| Accounts Payable | $8.7M | $8.1M | $4.8M | $8.1M | $6.4M | $6.4M | $4.1M | $8.4M |
| Total Current Liabilities | $64.5M | $72.8M | $64.5M | $62.5M | $39.1M | $34.3M | $24.4M | $74.3M |
| Long-Term Debt | $50.2M | — | — | — | — | — | — | — |
| Total Liabilities | $234.1M | $243.1M | $247.0M | $263.6M | $109.9M | $57.9M | $29.9M | $78.2M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.09B | $-1.02B | $-909.3M | $-743.8M | $-585.8M | $-455.7M | $-318.5M | $-231.6M |
| Total Stockholders' Equity | $11.8M | $39.5M | $81.9M | $206.0M | $341.2M | $123.6M | $246.9M | $203.0M |